By Dr. Maryam Nouhi, DO · Board-Certified Psychiatrist · Valor Mental Health · March 2026
Post-traumatic stress disorder is one of the most misunderstood conditions I see in my practice. Many people wait years — sometimes decades — before seeking treatment, often because they believe PTSD only affects combat veterans, or because they've tried one approach without success and concluded that nothing will help them. Neither is true.
PTSD affects approximately 9 million Americans at any given time, according to 2025 data from SingleCare. It develops in roughly 6% of the general population over a lifetime — but that number climbs to 11–23% among veterans. And critically: more than 40% of Americans living with PTSD and other serious mental health conditions remain completely untreated, largely due to access barriers, stigma, and confusion about where to start.
This article is my attempt to cut through that confusion. I'll walk you through what the evidence actually shows about PTSD treatment — what works reliably, what doesn't, and what to do when first-line approaches fall short.
PTSD is a psychiatric disorder that develops in some people after experiencing or witnessing a traumatic event — combat, sexual assault, a serious accident, childhood abuse, a natural disaster, a medical emergency, or any event that involved actual or threatened death, serious injury, or sexual violence.
Not everyone who experiences trauma develops PTSD. Resilience varies enormously between individuals and is influenced by genetics, prior trauma history, social support, and many other factors. PTSD is not a sign of weakness — it is a specific neurobiological response to overwhelming stress.
The DSM-5 criteria require symptoms in four clusters: re-experiencing (flashbacks, nightmares), avoidance (avoiding trauma reminders), negative changes in thinking and mood (persistent guilt, emotional numbness), and hyperarousal (startle response, hypervigilance, sleep disturbance). Symptoms must persist for more than one month and significantly impair functioning.
All major psychiatric and psychological bodies — the APA, VA/DoD, NICE, and ISTSS — agree that trauma-focused psychotherapy is the first-line treatment for PTSD. Three therapies have the most robust evidence:
CPT targets the maladaptive thoughts — "stuck points" — that develop after trauma. It helps patients examine beliefs like I should have stopped it or The world is completely dangerous and replace them with more balanced, accurate perspectives. CPT is typically delivered over 12 sessions and has strong evidence across diverse trauma populations, including sexual trauma and combat-related PTSD. It can be delivered via telehealth with equivalent results to in-person.
PE involves gradual, structured exposure to trauma memories and avoided situations — the opposite of what most PTSD patients instinctively want to do. Avoidance maintains PTSD; confronting memories in a safe therapeutic context reduces their power. PE typically runs 8–15 sessions. Evidence for PE is extensive, though dropout rates can be higher than CPT because the early sessions are emotionally demanding.
EMDR uses bilateral stimulation (typically eye movements) while the patient briefly attends to traumatic memories. The mechanism is still debated — some researchers believe the therapeutic effect comes from the exposure component rather than the eye movements themselves — but the outcome data is solid. EMDR is endorsed by the WHO and APA for PTSD and is particularly well-suited for patients who struggle to verbalize their trauma experience.
A note on non-trauma-focused therapies: general supportive therapy, non-directive counseling, and relaxation techniques can reduce distress but are not as effective as trauma-focused approaches for reducing core PTSD symptoms. If you've been in therapy for PTSD without meaningful improvement, it's worth asking whether the approach was specifically trauma-focused.
Medication plays an important role in PTSD — either as a primary treatment for patients who can't access or tolerate trauma-focused therapy, or as an adjunct that makes therapy more effective by reducing symptom severity.
Sertraline (Zoloft) and paroxetine (Paxil) are the only FDA-approved medications for PTSD. Both are selective serotonin reuptake inhibitors and work by modulating serotonin signaling — which plays a central role in fear memory, emotional regulation, and sleep. They take 6–8 weeks to show full effect and are generally well-tolerated. SSRIs reduce the full symptom cluster of PTSD, not just depression or anxiety components.
This SNRI — which affects both serotonin and norepinephrine — has substantial evidence for PTSD despite lacking FDA approval for this indication. Many guidelines, including VA/DoD, recommend it as a first-line option alongside SSRIs. It tends to be particularly helpful for patients with prominent hyperarousal symptoms.
PTSD-related nightmares are often undertreated. Prazosin, an alpha-1 adrenergic receptor blocker, has demonstrated efficacy for trauma nightmares and sleep disturbance in multiple trials. I frequently consider it for patients whose primary burden is sleep disruption — it can meaningfully improve quality of life even when core PTSD symptoms are still being addressed.
What I generally avoid in PTSD: benzodiazepines (Xanax, Klonopin, Valium). Despite their widespread use for anxiety, research consistently shows they do not improve PTSD outcomes, may impair the emotional processing needed for therapy to work, and carry significant risks of dependence. The VA/DoD guidelines specifically recommend against their use in PTSD.
This is where I want to be honest with you — because the treatment data is encouraging but not perfect.
Evidence-based trauma therapies produce meaningful symptom reduction in the majority of patients. Many people complete CPT or PE and no longer meet diagnostic criteria for PTSD. That's a remarkable outcome for a condition that once seemed permanent.
But roughly 30% of people don't benefit adequately from first-line PTSD treatments, according to research published in 2025. For SSRIs specifically, non-response rates range from 20–40%. CBT-based approaches can see dropout or non-response rates approaching 50% in some study populations, particularly among those with complex trauma histories or comorbid conditions.
What does this mean in practice? If one approach doesn't work, the answer is not to give up — it's to regroup and try another. Treatment-resistant PTSD is a clinical challenge, not a life sentence. I work with patients to identify why a prior approach may have failed and to build a more tailored plan that accounts for their full history, comorbidities, and preferences.
Many of the patients I see don't have textbook single-incident PTSD. They have histories of prolonged childhood abuse, domestic violence, or repeated institutional trauma — what clinicians sometimes call complex PTSD (C-PTSD). This presentation often involves emotional dysregulation, identity disruption, and interpersonal difficulties that go beyond the standard PTSD symptom clusters.
Complex PTSD typically requires a longer, more phased treatment approach — and a psychiatrist who understands the difference. Jumping straight into high-intensity exposure work without first stabilizing a patient's emotional regulation and safety can be counterproductive. Sequencing matters enormously.
PTSD also rarely travels alone. In my practice, I frequently see it co-occurring with:
These comorbidities must be assessed and addressed. Treating PTSD in isolation when a patient is also managing untreated depression or active alcohol use disorder will produce limited results.
Florida has a well-documented shortage of mental health providers relative to its population. Wait times for in-person psychiatric appointments can stretch weeks to months — a significant problem for a condition where early, sustained treatment produces the best outcomes.
Telepsychiatry has meaningfully changed this picture. At Valor Mental Health, I provide comprehensive psychiatric evaluation and medication management via secure video appointments for adults throughout Palm Beach and Broward Counties — often with same-week availability. You can be seen from your home, your car, or any private space with an internet connection.
My role in PTSD care is specifically the psychiatric component: comprehensive evaluation, diagnosis, medication management, comorbidity assessment, and coordination of care with your therapist. I do not provide weekly therapy myself — but I can connect you with trauma-specialized therapists in your area and work alongside them to optimize your overall treatment plan.
The strongest evidence supports trauma-focused psychotherapies — specifically Cognitive Processing Therapy (CPT), Prolonged Exposure (PE), and EMDR. For patients who need medication, FDA-approved SSRIs sertraline and paroxetine are first-line. Most patients benefit most from combining therapy and medication.
Medication can significantly reduce PTSD symptoms — including hyperarousal, sleep disturbance, and depression — but research consistently shows that combining medication with trauma-focused therapy produces the best long-term outcomes. Medication alone is rarely considered a complete treatment.
Treatment-resistant PTSD is real — roughly 30% of patients don't achieve adequate remission with first-line approaches. Options include switching to a different evidence-based therapy, augmenting with medication, or addressing comorbid conditions that may be blocking progress. A psychiatrist can assess what's been tried and tailor a plan accordingly.
Yes. Dr. Maryam Nouhi at Valor Mental Health provides comprehensive PTSD evaluation and psychiatric medication management via telepsychiatry for adults throughout Palm Beach and Broward Counties. She accepts UHC, Aetna, Optum, and Cigna. Call (561) 440-5242 to schedule.
Evidence-based trauma therapies like CPT and PE are typically completed in 12–16 sessions over 3–4 months. Medication trials take 6–8 weeks to assess effectiveness. Many patients see meaningful improvement within 3–6 months, though some require longer-term support — particularly those with complex or repeated trauma histories.